Abstract

Currently, stroke researchers are racing to develop neuroprotective strategies that shield the brain from ischemia-induced injury. To date, neuroprotective agents that have shown promise in animal studies have failed in clinical trials. Since the pathophysiology of ischemic stroke exploits numerous pathways leading to cellular injury, a combination of neuroprotective agents may offer substantially better results than a single agent alone - by intervening in multiple mechanisms. In this paper, we consider an approach using combination therapy with normobaric oxygen (NBO) and ethanol. Studies indicate that NBO therapy improves tissue oxygenation, thereby reducing the extent of hypoxic injury and decelerating the development of tissue necrosis when administered early after stroke onset. Studies have also demonstrated that low to moderate levels of ethanol not only decrease the risk of stroke, but also reduce post-ischemic sequelae. This article reviews the history of NBO and ethanol therapies, their mechanisms of action, the results of key clinical trials, and the rationale for their use as a combination therapy in the context of stroke treatment.

Full Text
Paper version not known

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call

Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.